Resmed - AI Stock Analysis

Analysis generated September 10, 2025

Resmed is a global leader in the development and manufacturing of medical devices and cloud-connected software applications aimed at improving the quality of life for the people who suffer from sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company has a strong commitment to research and development, enabling it to continually innovate and offer advanced solutions in its field.

Fundamental Analysis

Revenue: For the last quarter, Resmed reported revenue of $1.35 billion, marking an increase of 4.36% compared to the previous quarter and a 10.20% year-over-year growth. This consistent rise points to a robust growth trajectory for the company.

Net Income: The net income for the last quarter stood at $380 million, reflecting a 4.02% increase from the previous quarter and a significant 29.93% rise compared to the same quarter last year. Such substantial growth in net income highlights the company's ability to generate profits efficiently.

EBITDA: Resmed's EBITDA for the last quarter was $455 million, showing a 4.94% decline from the previous quarter. However, on a year-over-year basis, EBITDA increased by 7.70%, which aligns with the company's overall growth pattern.

P/E Ratio: The current Price-to-Earnings (P/E) ratio is 29.42. This relatively high P/E ratio could suggest that the stock is overvalued, posing a bearish outlook for potential investors.

Insider Activity: Recent insider selling of stock could be interpreted as a bearish signal, pointing to potentially cautious sentiment among those closely associated with the company.

Technical Analysis

Stock Price: Currently priced at $271.00, Resmed's stock has decreased by 4.34% compared to a month ago. However, it shows an 8.08% increase over the past year, indicating a positive long-term trend.

Moving Averages: The current Simple Moving Average over 10 days (SMA10) stands at 274.93, which is lower than the previous SMA10 of 275.28. This suggests a potential downward trend in price movement.

RSI: The Relative Strength Index (RSI) is 33.1, indicating a neutral condition. The RSI value suggests that the stock is neither overbought nor oversold, providing moderate confidence in maintaining its current trading range.

Alternative Data Analysis

Job Postings: Resmed currently has 418 open positions, up by 27% in the last couple of months. This indicates the company is looking to grow and expand, likely a positive sign for future business activities.

Employee Sentiment: The business outlook among employees is reported to be neutral, implying no extreme positive or negative sentiment within the workforce.

Customer Acquisition: Resmed's website has seen an estimated 2.9 million visitors, although the number is down by 23% in recent months. This is worrisome as it may indicate a loss in customer interest.

Customer Engagement: Resmed has 8,900 Instagram followers, up by 12% recently, showing an increased interest in the company's social media presence. Meanwhile, the Twitter follower count stands at 11,000 with no significant changes.

AI Score: According to AltIndex, Resmed has an AI score of 77, which is a buy signal. This score takes into account various fundamental, technical, and alternative data points.

Conclusion and Recommendation

In summary, Resmed presents a mixed bag of indicators. On the positive side, the company has shown a consistent increase in revenue and net income, coupled with a relatively high P/E ratio that could imply investor confidence. On the downside, declining EBITDA and recent insider selling are areas of concern. The technical analysis suggests a bearish trend in the short term, though the long-term prospects appear more favorable.

On the alternative data front, increasing job postings point to an expanding company, while a dip in web traffic is cautionary. The AI score of 77 indicating a buy signal provides some additional optimism.

Considering both the fundamental strengths and the cautionary signals from technical and alternative data, a generic recommendation would be to keep a close watch on Resmed for potential buying opportunities. Investors should consider current trends and market conditions before making any investment decision.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.